Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 Open-label Study of Doravirine/Islatravir 100 mg/0.25 mg in HIV-1 Infection
jRCT2051230002Phase 3Active, not recruiting
- Sponsor
- Merck & Co.
- Start
- Apr 2023
- Modality
- Small Molecules
01
Overview
Phase 3, open-label, single-arm trial of doravirine and islatravir in Human immunodeficiency virus infection type 1, sponsored by Merck & Co. Primary endpoints: Percentage of participants with one or more adverse event and Percentage of participants who discontinue study intervention due to an adverse event. Started Apr 2023; status: active, not recruiting.
02
Drugs
doravirineislatravir
03
Conditions
Human immunodeficiency virus infection type 1
Beyond the preview
Go deeper on jRCT2051230002.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2051230002.